Yao F, Gish R G
California Pacific Medical Center, 2340 Clay Street, Suite 251, San Francisco, CA 94115, USA.
Curr Gastroenterol Rep. 1999 Feb-Mar;1(1):20-6. doi: 10.1007/s11894-999-0082-7.
Chronic hepatitis B infection is the most important cause of cirrhosis and hepatocellular carcinoma worldwide. Interferon-alpha has been shown to be effective in approximately one third of patients, and response seems to be sustained in long-term follow-up studies in Western countries. New treatments using lamivudine and other nucleoside analogues such as famciclovir, lobucavir, and adfovir showed promising results although sustained suppression of viral replication is unusual after discontinuation of therapy. The results of recent clinical studies using these nucleoside analogues are discussed in detail in this review. Other important issues such as drug resistance and the role of combination therapy are also addressed.
慢性乙型肝炎感染是全球肝硬化和肝细胞癌的最重要病因。α干扰素已被证明在约三分之一的患者中有效，并且在西方国家的长期随访研究中，疗效似乎能够持续。使用拉米夫定和其他核苷类似物（如泛昔洛韦、洛布卡韦和阿德福韦）的新疗法显示出了有前景的结果，尽管在治疗中断后病毒复制的持续抑制并不常见。本综述详细讨论了近期使用这些核苷类似物的临床研究结果。还探讨了其他重要问题，如耐药性和联合治疗的作用。
